Novel peptide‐based vaccines efficiently prime murine “help”‐independent CD8+ T cell responses in the liver
Nektarios Dikopoulos, Petra Riedl, Reinhold Schirmbeck, Jörg Reimann – 13 August 2004 – Vaccines for the prophylactic and/or therapeutic immunization against hepatotropic pathogens (e.g., hepatitis B and hepatitis C virus) should establish long‐lasting, specific antiviral effector/memory CD8+ T cell immunity in the liver. We describe a novel peptide‐based vaccine in which antigenic major histocompatibility complex Class I–binding peptides are fused to a cationic (e.g., human immunodeficiency virus tat‐derived) domain and complexed to immune‐stimulating oligonucleotides.